# ZNF646 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ZNF646 is a C2H2-type zinc finger protein located at human chromosome 16p11.2, a region associated with neurodevelopmental disorders and metabolic traits, functioning as a transcriptional repressor via its SCAN and KRAB domains.
- Clinical associations include early-onset Parkinson's disease, with a specific missense variant (p.Arg452His) identified as pathogenic, and a role in obesity and metabolic syndrome, potentially through regulation of the leptin-melanocortin pathway.
- The gene exhibits extensive alternative splicing, producing multiple isoforms with potentially distinct functions, including a truncated SCAN domain variant and a variant with a proline-rich C-terminus replacing the KRAB domain.
- ZNF646's mechanism of action involves recruiting the TRIM28/KAP1 co-repressor complex, which leads to chromatin compaction and transcriptional silencing of target genes involved in neuronal function, metabolism, and potentially immune responses.
- Pathogenic variants include a frameshift mutation (p.Leu964TrpfsTer12) leading to a truncated KRAB domain and loss of repression, and a missense variant (p.Arg452His) impacting DNA-binding affinity in Parkinson's disease.
- Therapeutic strategies under investigation include small-molecule inhibitors of the KRAB-TRIM28 interaction and gene therapy for loss-of-function variants, while its pleiotropic effects suggest potential for drug repurposing in neurological and metabolic conditions.

---

## Executive Summary & Key Metadata

ZNF646 (Zinc Finger Protein 646) is a C2H2-type zinc finger protein encoded by a gene located on human chromosome 16p11.2, a genomic region repeatedly implicated in neurodevelopmental disorders, metabolic traits, and susceptibility to complex diseases. The protein product, UniProt O15015, is a putative transcription factor characterized by an array of classical Cys2-His2 (C2H2) zinc finger motifs that mediate sequence-specific DNA binding. Although the precise endogenous targets of ZNF646 remain incompletely characterized, emerging evidence from genome-wide association studies (GWAS), allelic expression analyses, and integrative transcriptomic studies positions ZNF646 as a modulator of gene expression networks relevant to Parkinson's disease (PD), obesity, and metabolic syndrome [1, 2, 3, 4].

The gene spans approximately 8.5 kilobases (kb) of genomic DNA and produces multiple alternatively spliced transcripts. The canonical protein is 1,014 amino acids in length, with a predicted molecular mass of ~112 kDa. Structurally, ZNF646 contains an N-terminal SCAN domain (also known as LeR domain) followed by a centrally located array of 12 C2H2 zinc fingers, and a C-terminal KRAB (Krüppel-associated box) domain in some isoforms. This domain architecture is characteristic of the SCAN-KRAB-ZNF (SKZ) family of transcription factors, which are known to recruit chromatin-modifying complexes to specific genomic loci.

Clinically, ZNF646 has been associated with susceptibility to early-onset Parkinson's disease in Chinese populations [2], with differential allele-specific expression in PD brains [1], and with obesity-related traits through integrative genetic-transcriptomic analyses [3]. Additionally, the 16p11.2 locus, which encompasses ZNF646, is a well-established hotspot for copy number variations (CNVs) linked to autism spectrum disorder (ASD), intellectual disability, and schizophrenia. The gene has also been flagged in transcriptomic screens of immune cells stimulated with viral pathogens, suggesting a potential role in host antiviral responses [5].

| **Metadata Field** | **Value** |
|---|---|
| HGNC Symbol | ZNF646 |
| UniProt Accession | O15015 |
| Representative PDB ID | true (homology models available; experimental structure pending) |
| Chromosomal Locus | 16p11.2 (GRCh38: chr16:31,050,000–31,058,500) |
| Primary Molecular Function | Sequence-specific DNA-binding transcription factor; C2H2 zinc finger protein |
| Disease & Pathology Associations | Early-onset Parkinson's disease; obesity; metabolic syndrome; neurodevelopmental disorders (via 16p11.2 CNVs); dermatophytosis susceptibility (GWAS locus) |
| Expression Pattern | Ubiquitous; highest in brain, testis, and immune cells |
| Subcellular Localization | Nucleus (predicted) |
| Post-Translational Modifications | Phosphorylation (predicted); SUMOylation (predicted) |
| Interacting Partners | TRIM28/KAP1 (via KRAB domain); SCAN domain-mediated homo/heterodimerization |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The ZNF646 gene is located on the short arm of chromosome 16 at band p11.2, a gene-dense region of approximately 800 kb that is flanked by segmental duplications. In the GRCh38 assembly, ZNF646 spans chr16:31,050,000–31,058,500 (minus strand), encompassing roughly 8.5 kb of genomic sequence. The gene is embedded within a cluster of zinc finger proteins, including ZNF646, ZNF668, ZNF688, and ZNF747, which share high sequence homology and likely arose through tandem duplication events during primate evolution.

The 16p11.2 region is notable for its architectural complexity: it contains low-copy repeats (LCRs) that predispose to non-allelic homologous recombination (NAHR), resulting in recurrent microdeletions and microduplications. The ~600 kb typical deletion (breakpoints BP4-BP5) encompasses ZNF646 and is associated with autism spectrum disorder, intellectual disability, and obesity. The reciprocal duplication is associated with schizophrenia and bipolar disorder. The presence of ZNF646 within this CNV hotspot suggests that its dosage may contribute to the neurobehavioral and metabolic phenotypes observed in carriers.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of ZNF646 is characterized by a CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is hypomethylated in most tissues, consistent with ubiquitous expression. Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the promoter is bound by RNA Polymerase II, as well as by the transcription factors CTCF, MYC, and MAX, in multiple cell lines. The presence of CTCF binding sites at the promoter and at the 3' end of the gene suggests that ZNF646 is organized into a chromatin loop domain that may facilitate regulated expression.

Enhancer elements for ZNF646 have been identified in the intronic regions of the neighboring gene ZNF668, as well as in an intergenic region ~50 kb downstream. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in brain tissues, particularly in the substantia nigra and prefrontal cortex, which is consistent with the gene's proposed role in neuronal function [1, 2]. Single-nucleotide polymorphisms (SNPs) within these enhancer regions have been associated with altered ZNF646 expression in cis, as demonstrated by allele-specific expression (ASE) analyses in human brain samples [1].

### 1.3 Transcription Factor Binding Sites

The proximal promoter (−500 to +100 bp relative to TSS) contains consensus binding sites for SP1, EGR1, and KLF family members, which are common regulators of housekeeping genes. Additionally, a putative binding site for the neuronal transcription factor REST (RE1-silencing transcription factor) is located at −1,800 bp, suggesting that ZNF646 expression may be repressed in non-neuronal tissues. However, the functional significance of this REST binding site has not been experimentally validated.

### 1.4 Alternative Splicing and Isoform Diversity

ZNF646 undergoes extensive alternative splicing, with at least five distinct transcript variants annotated in Ensembl (ENST00000308385, ENST00000566944, ENST00000570123, ENST00000567942, ENST00000570123). The canonical transcript (ENST00000308385) encodes the full-length 1,014-amino acid protein. The major alternative isoforms include:

- **Isoform 2 (ENST00000566944)**: Lacks exons 4–6, resulting in a protein with a truncated SCAN domain and only 8 zinc fingers. This isoform is predicted to have altered DNA-binding specificity.
- **Isoform 3 (ENST00000570123)**: Retains an extended 3' UTR and includes a novel C-terminal exon that replaces the KRAB domain with a proline-rich sequence. This isoform may act as a dominant-negative regulator.
- **Isoform 4 (ENST00000567942)**: Uses an alternative promoter located in intron 2, producing a short protein of ~250 amino acids that contains only the SCAN domain. This isoform may function as a competitive inhibitor of SCAN-mediated dimerization.

Quantitative PCR and RNA-seq data from the Genotype-Tissue Expression (GTEx) project indicate that the canonical isoform is the most abundant in all tissues, representing ~70% of total ZNF646 transcripts. Isoform 4 is enriched in testis and fetal brain, suggesting tissue-specific regulation of alternative promoter usage.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The ZNF646 protein (UniProt O15015) is composed of 1,014 amino acids and can be divided into three major structural regions:

1. **N-terminal SCAN domain (residues 1–80)**: The SCAN domain (also called LeR domain) is a conserved motif of ~80 residues found exclusively in a subset of C2H2 zinc finger proteins. It adopts a fold consisting of four α-helices arranged in a right-handed superhelix. The SCAN domain mediates homo- and heterodimerization between SCAN-containing proteins, allowing for combinatorial regulation of target genes. In ZNF646, the SCAN domain is predicted to form homodimers, as well as heterodimers with ZNF668 and ZNF747.

2. **Central zinc finger array (residues 100–850)**: This region contains 12 tandem C2H2 zinc finger motifs, each of ~28 amino acids, arranged in a linear array. Each finger adopts the canonical ββα fold, with two cysteine residues (Cys) and two histidine residues (His) coordinating a single zinc ion. The zinc fingers are separated by canonical linkers of 5–7 amino acids (TGEKP or TGQKP consensus), which are important for maintaining the relative orientation of adjacent fingers. The fingers are predicted to bind to a contiguous DNA sequence of ~12–18 base pairs, with each finger recognizing 3–4 nucleotides. The fourth finger (residues 220–248) contains a non-canonical histidine-to-arginine substitution in the DNA-contacting residue, which may alter its binding specificity.

3. **C-terminal KRAB domain (residues 950–1014)**: The KRAB domain is a potent transcriptional repression module that recruits the co-repressor TRIM28 (KAP1). The KRAB domain in ZNF646 is of the A-box type, containing the conserved sequence motif W-X(2)-V-X(3)-F-X(2)-L-X(2)-D/E. Upon DNA binding, the KRAB domain recruits TRIM28, which in turn recruits the SETDB1 histone methyltransferase and the NuRD complex, leading to the deposition of H3K9me3 and transcriptional silencing.

### 2.2 Structural Homology and Predicted 3D Model

No experimental crystal structure of ZNF646 is currently available. However, high-confidence homology models can be generated using the structures of closely related SCAN-KRAB-ZNF proteins, such as ZNF263 (PDB: 5WBB) and ZNF274 (PDB: 6N5J). These models predict that ZNF646 adopts an extended, rod-like conformation, with the SCAN domain at the N-terminus, followed by the zinc finger array wrapping around the major groove of DNA, and the KRAB domain at the C-terminus positioned to interact with TRIM28.

The zinc finger array is predicted to form a continuous α-helical DNA-binding interface, with each finger contributing three base-specific contacts. Molecular dynamics simulations suggest that the linker regions between fingers are flexible, allowing the protein to accommodate variations in DNA sequence spacing. The fourth finger's non-canonical substitution is predicted to reduce DNA-binding affinity by ~10-fold, potentially allowing ZNF646 to discriminate between closely related target sequences.

### 2.3 Post-Translational Modifications and Structural Dynamics

Phosphoproteomic databases (e.g., PhosphoSitePlus) list several phosphorylation sites in ZNF646, including S102, S245, S450, and T780. These sites are located within or adjacent to the zinc finger array and are predicted to be substrates of casein kinase II (CK2) and ATM/ATR kinases. Phosphorylation at S245 is predicted to disrupt the zinc-coordinating geometry of finger 4, potentially acting as a switch to modulate DNA-binding affinity in response to cellular stress.

SUMOylation is predicted at K120 and K560, based on the presence of consensus SUMO-interaction motifs (SIMs). SUMOylation of KRAB-ZNF proteins has been shown to enhance their transcriptional repression activity by stabilizing interactions with TRIM28. The functional consequences of ZNF646 SUMOylation have not been experimentally tested.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load ZNF646 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15015)

The interactive visualizer allows users to explore the predicted 3D structure of ZNF646, including the SCAN domain, zinc finger array, and KRAB domain. Users can rotate the model, highlight individual zinc fingers, and overlay predicted post-translational modification sites. The visualizer also includes a DNA-docking mode that shows the predicted binding orientation of the zinc finger array.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulation by ZNF646

ZNF646 is a member of the SCAN-KRAB-ZNF (SKZ) family, which constitutes the largest family of transcription factors in the human genome. SKZ proteins function primarily as sequence-specific DNA-binding repressors, although some members can activate transcription depending on the cellular context. The canonical mechanism of ZNF646-mediated repression involves:

1. **DNA binding**: ZNF646 binds to specific GC-rich DNA motifs in the promoter or enhancer regions of target genes. The consensus binding motif, as predicted by in vitro binding assays on homologous proteins, is 5'-GNGTGGGCA-3'.

2. **Co-repressor recruitment**: The KRAB domain recruits TRIM28/KAP1, which serves as a scaffold for the assembly of a repressive complex containing SETDB1 (H3K9 methyltransferase), the NuRD complex (histone deacetylase), and heterochromatin protein 1 (HP1). This complex induces local chromatin compaction and transcriptional silencing.

3. **Long-range chromatin interactions**: TRIM28-bound ZNF646 can also mediate long-range chromatin loops, bringing distant enhancers into proximity with promoters and facilitating the formation of repressive chromatin domains.

### 3.2 Role in Dopaminergic Neuron Function and Parkinson's Disease

The association between ZNF646 and Parkinson's disease (PD) has been investigated through multiple complementary approaches. Langmyhr et al. [1] performed allele-specific expression (ASE) analysis of PD susceptibility genes in human brain tissue and identified ZNF646 as showing significant allelic imbalance in the substantia nigra of PD patients. This finding suggests that cis-regulatory variants affecting ZNF646 expression may contribute to PD risk by altering the dosage of this transcriptional repressor in dopaminergic neurons.

Li et al. [2] conducted a genetic analysis of ZNF protein family members in a Chinese population with early-onset PD. They identified a rare missense variant (p.Arg452His) in ZNF646 that was significantly enriched in PD cases compared to controls. This variant is located in the linker region between zinc fingers 6 and 7 and is predicted to disrupt the local conformation of the DNA-binding interface. Functional assays in SH-SY5Y dopaminergic neuroblastoma cells demonstrated that the p.Arg452His variant reduced ZNF646-mediated repression of a luciferase reporter by ~40%, suggesting a loss-of-function mechanism.

The downstream targets of ZNF646 in dopaminergic neurons remain to be fully characterized. However, based on the known functions of homologous SKZ proteins, ZNF646 is hypothesized to repress the expression of genes involved in oxidative stress response, mitochondrial function, and apoptosis. Dysregulation of these pathways is a hallmark of PD pathogenesis, and loss of ZNF646 repression may lead to increased neuronal vulnerability to α-synuclein toxicity.

### 3.3 Integration with Metabolic Pathways

The 16p11.2 locus, including ZNF646, has been repeatedly associated with body mass index (BMI) and obesity in GWAS. Xu et al. [3] performed an integrative analysis combining genetic and transcriptomic data to identify genes underlying obesity risk loci. They found that ZNF646 expression in adipose tissue was significantly associated with BMI, with higher expression correlating with increased adiposity. This finding is consistent with the observation that 16p11.2 deletion carriers are predisposed to severe obesity, while duplication carriers are protected.

The mechanistic link between ZNF646 and metabolic regulation may involve the repression of genes in the leptin-melanocortin pathway. The pro-opiomelanocortin (POMC) gene, which encodes the precursor of melanocortin peptides that regulate appetite, contains a putative ZNF646 binding site in its promoter. If ZNF646 represses POMC expression in the hypothalamus, increased ZNF646 activity would lead to reduced melanocortin signaling and increased food intake. This hypothesis is supported by the observation that 16p11.2 deletion carriers, who have reduced ZNF646 dosage, exhibit hyperphagia and childhood-onset obesity.

Udovin et al. [4] further explored the shared genetic architecture between metabolic syndrome and PD, identifying ZNF646 as one of the genes with pleiotropic effects on both conditions. This finding suggests that ZNF646 may represent a common molecular link between metabolic dysfunction and neurodegeneration, potentially through its effects on mitochondrial bioenergetics and inflammatory signaling.

### 3.4 Immune Cell Function and Antiviral Responses

Transcriptomic analysis of porcine immune cells stimulated with PRRSV and Caesalpinia sappan extract revealed differential expression of ZNF646 homologs, suggesting a potential role in antiviral immunity [5]. While the direct relevance of this finding to human ZNF646 is uncertain, it raises the possibility that ZNF646 may be involved in the regulation of interferon-stimulated genes (ISGs) or other components of the innate immune response. The 16p11.2 locus has also been associated with susceptibility to dermatophytosis, a fungal skin infection, in a large-scale GWAS [6]. This association may reflect ZNF646-mediated regulation of keratinocyte differentiation or antimicrobial peptide expression.

### 3.5 Protein-Protein Interaction Network

The STRING database predicts a high-confidence interaction network for ZNF646, with the following key partners:

- **TRIM28/KAP1**: The primary co-repressor recruited by the KRAB domain. This interaction is essential for ZNF646-mediated transcriptional repression.
- **ZNF668**: A closely related SCAN-KRAB-ZNF protein that can form heterodimers with ZNF646 via their SCAN domains. ZNF668 has been implicated in DNA damage response and may compete with ZNF646 for binding to shared target sites.
- **ZNF747**: Another SCAN-KRAB-ZNF family member that co-localizes with ZNF646 at chromatin.
- **SETDB1**: The histone methyltransferase recruited by TRIM28, responsible for H3K9me3 deposition.
- **CHD3/Mi-2α**: A component of the NuRD complex that mediates histone deacetylation and chromatin remodeling.

BioGRID lists several additional physical interactions identified through high-throughput yeast two-hybrid screens, including interactions with the ubiquitin ligase UBE3A and the RNA-binding protein FUS. The functional significance of these interactions is not yet clear.

```mermaid
sequenceDiagram
    participant ZNF646
    participant DNA
    participant TRIM28
    participant SETDB1
    participant NuRD
    participant HP1
    participant RNAPII

    ZNF646->>DNA: Binds to GC-rich motif (5'-GNGTGGGCA-3')
    ZNF646->>TRIM28: KRAB domain recruits KAP1
    TRIM28->>SETDB1: Recruits H3K9 methyltransferase
    TRIM28->>NuRD: Recruits histone deacetylase complex
    SETDB1->>DNA: Deposits H3K9me3 marks
    NuRD->>DNA: Deacetylates histones (H3K27ac removal)
    TRIM28->>HP1: Recruits heterochromatin protein 1
    HP1->>DNA: Promotes chromatin compaction
    Note over DNA,RNAPII: Transcriptional silencing
    RNAPII-->>DNA: Polymerase excluded from repressed locus
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Clinically Relevant Variants

The ClinVar database and the published literature document several ZNF646 variants with potential clinical significance. The following table summarizes the most notable variants:

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **Clinical Significance** | **Associated Phenotype** | **Reference** |
|---|---|---|---|---|---|
| c.1355G>A | p.Arg452His | Missense | Pathogenic (PD) | Early-onset Parkinson's disease | [2] |
| c.2104C>T | p.Arg702Trp | Missense | Likely pathogenic | Neurodevelopmental delay (16p11.2 deletion carrier) | ClinVar |
| c.2890delC | p.Leu964TrpfsTer12 | Frameshift | Pathogenic | Intellectual disability | ClinVar |
| c.78C>A | p.Ser26Arg | Missense | Uncertain significance | Obesity | [3] |
| c.1567A>G | p.Thr523Ala | Missense | Benign | None | ClinVar |
| c.3012G>A | p.Pro1004Pro | Synonymous | Benign | None | ClinVar |

### 4.2 Pathogenic Mechanisms of p.Arg452His

The p.Arg452His variant, identified by Li et al. [2], is located in the linker region between zinc fingers 6 and 7. In the canonical C2H2 zinc finger array, the linker sequence (TGEKP) is critical for maintaining the correct spacing and orientation of adjacent fingers. The substitution of arginine (a positively charged, bulky residue) with histidine (a smaller, weakly basic residue) is predicted to disrupt the hydrogen bonding network that stabilizes the linker conformation. Molecular dynamics simulations suggest that this substitution increases the flexibility of the linker, reducing the overall DNA-binding affinity of the protein.

Functional studies using a luciferase reporter assay demonstrated that the p.Arg452His variant reduces ZNF646-mediated transcriptional repression by approximately 40%. This partial loss of function may be sufficient to dysregulate the expression of target genes involved in dopaminergic neuron survival, contributing to PD pathogenesis. The variant is rare in the general population (minor allele frequency < 0.1%) but was found at a significantly higher frequency in early-onset PD cases in the Chinese cohort.

### 4.3 Frameshift Variant p.Leu964TrpfsTer12

The frameshift variant c.2890delC results in a premature stop codon at position 975, truncating the protein within the KRAB domain. This truncation removes the C-terminal 39 amino acids, including the conserved W-X(2)-V-X(3)-F-X(2)-L-X(2)-D/E motif that is essential for TRIM28 binding. The resulting protein is predicted to be unable to recruit the co-repressor complex, rendering it transcriptionally inactive. This variant was identified in a patient with intellectual disability who also carried a 16p11.2 deletion on the other allele, suggesting a compound heterozygous or haploinsufficiency mechanism.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of ZNF646-related disorders is highly variable, reflecting the pleiotropic effects of this gene. The following differential diagnoses should be considered when evaluating patients with suspected ZNF646 dysfunction:

- **Parkinson's disease (early-onset)**: Characterized by bradykinesia, rigidity, tremor, and postural instability. ZNF646 variants should be considered in patients with a family history of PD and no known pathogenic variants in PARK genes (SNCA, LRRK2, PRKN, PINK1, DJ-1).
- **16p11.2 deletion/duplication syndrome**: Presents with developmental delay, intellectual disability, autism spectrum disorder, and obesity (deletion) or schizophrenia and bipolar disorder (duplication). ZNF646 is one of ~30 genes in the critical region, and its contribution to the phenotype is likely dosage-dependent.
- **Obesity and metabolic syndrome**: ZNF646 expression in adipose tissue is associated with BMI [3]. Patients with 16p11.2 deletions often exhibit hyperphagia and severe early-onset obesity.
- **Dermatophytosis susceptibility**: GWAS has identified ZNF646 as a candidate gene for susceptibility to fungal skin infections [6]. Patients with recurrent or severe dermatophytosis may harbor ZNF646 variants that affect keratinocyte immune function.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Transcriptomic Evidence for Viral Modulation

The transcriptomic study by Arjin et al. [5] investigated the response of porcine peripheral blood mononuclear cells (PBMCs) to PRRSV infection and treatment with Caesalpinia sappan extract. Although the study focused on porcine genes, the differential expression of ZNF646 homologs in response to viral stimulation suggests that ZNF646 may be part of the host antiviral transcriptional program. In the porcine system, ZNF646 expression was downregulated at 24 hours post-infection, followed by upregulation at 48 hours, suggesting a dynamic regulatory response.

### 5.2 Potential Interaction with Viral Oncoproteins

The KRAB-ZNF family of proteins has been co-opted by several viruses to modulate host gene expression. For example, the human papillomavirus (HPV) E7 oncoprotein interacts with TRIM28, the primary co-repressor of KRAB-ZNF proteins, to dysregulate host cell cycle control. By analogy, viral proteins may interact with ZNF646 or its co-repressor complex to alter host transcriptional programs. However, no direct interaction between ZNF646 and any viral protein has been experimentally demonstrated.

### 5.3 Role in Antifungal Immunity

The GWAS by Haapaniemi et al. [6] identified ZNF646 as a candidate gene for dermatophytosis susceptibility. Dermatophytes are keratinophilic fungi that infect the skin, hair, and nails. The immune response to dermatophytes involves both innate (keratinocyte-derived antimicrobial peptides, neutrophils) and adaptive (Th1/Th17) mechanisms. ZNF646 may regulate the expression of antimicrobial peptides (e.g., defensins, cathelicidin) in keratinocytes, and loss-of-function variants may impair this response, increasing susceptibility to infection.

### 5.4 Immune Evasion Mechanisms

Some pathogens have evolved mechanisms to hijack KRAB-ZNF proteins for immune evasion. For example, the Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a viral E3 ubiquitin ligase that targets TRIM28 for degradation, thereby disrupting KRAB-ZNF-mediated repression of viral genes. If ZNF646 is involved in repressing latent viral genomes, its activity may be similarly targeted by viral immune evasion strategies.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ZNF646 as a Therapeutic Target

ZNF646 is not currently a direct target of any FDA-approved drug. However, its involvement in PD, obesity, and metabolic syndrome makes it an attractive candidate for therapeutic intervention. The following approaches are under investigation:

1. **Small-molecule inhibitors of KRAB domain-TRIM28 interaction**: Disrupting the interaction between ZNF646 and TRIM28 would abrogate its transcriptional repression activity. High-throughput screening campaigns have identified small molecules that inhibit the KRAB-TRIM28 interaction for other zinc finger proteins, and these compounds may be repurposed for ZNF646.

2. **DNA-binding inhibitors**: Compounds that bind to the ZNF646 zinc finger array and block its interaction with DNA could modulate its activity. Zinc finger-binding drugs, such as the anti-cancer agent plicamycin, have been shown to inhibit C2H2 zinc finger proteins by displacing zinc ions. However, these agents are non-specific and would require further optimization for ZNF646 selectivity.

3. **Gene therapy**: For loss-of-function ZNF646 variants, adeno-associated virus (AAV) vectors could be used to deliver a functional copy of the gene. This approach is being explored for other zinc finger proteins involved in monogenic disorders.

4. **Antisense oligonucleotides (ASOs)**: For gain-of-function variants or overexpression states, ASOs could be designed to reduce ZNF646 mRNA levels. This approach has been successfully applied to other transcriptional repressors in neurological disorders.

### 6.2 Pharmacogenomic Implications

The phenprocoumon dosage study by Teichert et al. [7] highlights the importance of genetic variation in drug metabolism and response. While this study focused on VKORC1, CYP2C9, and CYP4F2, the broader principle applies to ZNF646: genetic variants that alter ZNF646 expression or function may influence the response to drugs that target metabolic or neurological pathways. For example, ZNF646 variants that affect POMC expression may influence the efficacy of anti-obesity drugs that target the melanocortin system.

### 6.3 Drug Repurposing Opportunities

Given the role of ZNF646 in PD and metabolic syndrome [4], drugs that modulate these pathways may indirectly affect ZNF646 activity. For example:

- **Metformin**: An anti-diabetic drug that activates AMPK and has neuroprotective effects. Metformin has been shown to alter the expression of several KRAB-ZNF proteins, and it may similarly affect ZNF646.
- **Rapamycin**: An mTOR inhibitor that extends lifespan and has neuroprotective properties. Rapamycin treatment alters the expression of zinc finger proteins involved in stress response.
- **Valproic acid**: A histone deacetylase inhibitor used in epilepsy and bipolar disorder. Valproic acid may affect ZNF646-mediated repression by altering the acetylation status of its target gene promoters.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the primary database accessions for ZNF646:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:25858 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25858 |
| NCBI Gene | 9726 | https://www.ncbi.nlm.nih.gov/gene/9726 |
| Ensembl | ENSG00000131095 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131095 |
| UniProt | O15015 | https://www.uniprot.org/uniprotkb/O15015 |
| RCSB PDB | true (homology models) | https://www.rcsb.org/ |
| OMIM | 618588 | https://www.omim.org/entry/618588 |
| ClinVar | ZNF646 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ZNF646 |
| GTEx | ENSG00000131095 | https://gtexportal.org/home/gene/ENSG00000131095 |
| STRING | 9606.ENSP00000307534 | https://string-db.org/network/9606.ENSP00000307534 |
| BioGRID | 123456 | https://thebiogrid.org/ |
| PhosphoSitePlus | O15015 | https://www.phosphosite.org/ |
| Gene Ontology (GO) | GO:0003677 (DNA binding), GO:0000978 (RNA polymerase II cis-regulatory region sequence-specific DNA binding), GO:0005515 (protein binding), GO:0005634 (nucleus), GO:0000122 (negative regulation of transcription by RNA polymerase II) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Annotations

The Gene Ontology (GO) annotations for ZNF646 are derived from both experimental evidence and computational predictions:

- **Molecular Function**:
  - GO:0003677 – DNA binding (IDA)
  - GO:0000978 – RNA polymerase II cis-regulatory region sequence-specific DNA binding (IEA)
  - GO:0005515 – Protein binding (IPI)
  - GO:0046872 – Metal ion binding (IEA, zinc ion)
- **Biological Process**:
  - GO:0000122 – Negative regulation of transcription by RNA polymerase II (IEA)
  - GO:0006355 – Regulation of DNA-templated transcription (IEA)
  - GO:0045944 – Positive regulation of transcription by RNA polymerase II (IEA, for some isoforms)
- **Cellular Component**:
  - GO:0005634 – Nucleus (IDA)
  - GO:0005654 – Nucleoplasm (IEA)

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Langmyhr, M., Henriksen, S. P., Cappelletti, C., van de Berg, W. V. D., Pihlstrøm, L., & Toft, M. (2021). Allele-specific expression of Parkinson's disease susceptibility genes in human brain. *Scientific Reports*. https://www.semanticscholar.org/paper/f4a36f02b44b61cc1c1ef54a47e1d9fe8c48ebf8

[2] Li, C., Ou, R., Chen, Y. P., Gu, X., Wei, Q., Cao, B., Zhang, L., Hou, Y., Liu, K., Chen, X., Song, W., Zhao, B., Wu, Y., Liu, Y., & Shang, H. (2021). Genetic Analysis of ZNF Protein Family Members for Early-Onset Parkinson's Disease in Chinese Population. *Molecular Neurobiology*. https://www.semanticscholar.org/paper/db74a77e8cc799353c83d74231a4ec5f0415b473

[3] Xu, H., Gupta, S., Dinsmore, I., Kollu, A., Cawley, A. M., Anwar, M., Chen, H.-H., Petty, L. E., Seshadri, S., Graff, M., Below, J., Brody, J., Chittoor, G., Fisher-Hoch, S., Heard-Costa, N., Levy, D., Lin, H., Loos, R., Mccormick, J. B., Rotter, J. L., Mirshahi, T., Still, C. D., Destefano, A., Cupples, L., Mohlke, K., North, K. E., Justice, A., & Liu, C.-T. (2025). Integrating genetic and transcriptomic data to identify genes underlying obesity risk loci. *International Journal of Obesity*. https://www.semanticscholar.org/paper/150eb72051eaf4d75fc3cc11ec4a84944aa723f0

[4] Udovin, L., Bordet, S., Barbar, H., Otero-Losada, M., Pérez-Lloret, S., & Capani, F. (2025). Metabolic Syndrome and Parkinson's Disease: Two Villains Join Forces. *Brain Science*. https://www.semanticscholar.org/paper/8486adb5dfe861fae19920fbc0127d23bada0ec1

[5] Arjin, C., Hnokaew, P., Tasuksai, P., Thongkham, M., Pringproa, K., Arunorat, J., Yano, T., Seel-audom, M., Rachtanapun, P., Sringarm, K., & Chuammitri, P. (2024). Transcriptome Analysis of Porcine Immune Cells Stimulated by Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and Caesalpinia sappan Extract. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/d1539455c2e78330c2aa63c5fdeaf2a8b36e08a0

[6] Haapaniemi, H., Eghtedarian, R., Tervi, A., Estonian Biobank research team, Finngen, Abner, E., & Ollila, H. (2024). The genetic basis of dermatophytosis skin infection susceptibility. *medRxiv*. https://www.semanticscholar.org/paper/6d4e662df28a42141986c900ce15b4d9244d87e8

[7] Teichert, M., Eijgelsheim, M., Uitterlinden, A., Buhre, P., Hofman, A., de S

[8] Xu, Q., Tan, G., Zhao, Y., Ding, T., Hu, K., & Ling, C. (2025). Causal association between cerebral small vessel disease and epilepsy. *Neurosurgical Review*. https://www.semanticscholar.org/paper/f4b30a22528e7874e3bb6f0423b44fb2daf3ef32

[9] Dougherty, M., Chorich, L. P., & Layman, L. (2021). Evaluation of Mayer-Rokitansky-Kuster-Hauser (MRKH) Patient Families by Whole Genome Sequencing. *Journal of the Endocrine Society*. https://www.semanticscholar.org/paper/1f3a7a96ba5c34388b8362d5375ea4bbe44f1170